A Study of the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
Phase 1
Completed
- Conditions
- Migraine Without AuraMigraine With AuraMigraine
- Interventions
- First Posted Date
- 2022-04-20
- Last Posted Date
- 2022-04-20
- Lead Sponsor
- Satsuma Pharmaceuticals, Inc.
- Target Recruit Count
- 36
- Registration Number
- NCT05337254
- Locations
- ๐บ๐ธ
Quotient Sciences Miami Inc., Miami, Florida, United States
A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess STS101 in the Acute Treatment of Migraine
Phase 3
Completed
- Conditions
- Migraine With AuraMigraine Without AuraMigraine
- Interventions
- Drug: DihydroergotamineDrug: Placebo
- First Posted Date
- 2021-06-25
- Last Posted Date
- 2023-11-27
- Lead Sponsor
- Satsuma Pharmaceuticals, Inc.
- Target Recruit Count
- 1591
- Registration Number
- NCT04940390
- Locations
- ๐บ๐ธ
DM Clinical Research, Tomball, Texas, United States
๐บ๐ธDowntown LA Research Center, Los Angeles, California, United States
๐บ๐ธPalm Beach Research, West Palm Beach, Florida, United States
A Study to Evaluate the Safety of STS101 in the Acute Treatment of Migraine
Phase 3
Completed
- Conditions
- MigraineMigraine With AuraMigraine Without Aura
- Interventions
- First Posted Date
- 2020-05-28
- Last Posted Date
- 2023-07-03
- Lead Sponsor
- Satsuma Pharmaceuticals, Inc.
- Target Recruit Count
- 482
- Registration Number
- NCT04406649
- Locations
- ๐บ๐ธ
ClinCloud, Maitland, Florida, United States
๐บ๐ธCNS Health Care - Orlando, Orlando, Florida, United States
๐บ๐ธAdvanced Clinical Research, Meridian, Idaho, United States
A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate STS101 in the Acute Treatment of Migraine
Phase 3
Completed
- Conditions
- MigraineMigraine With AuraMigraine Without Aura
- Interventions
- Drug: PlacebosDrug: Dihydroergotamine
- First Posted Date
- 2019-04-03
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- Satsuma Pharmaceuticals, Inc.
- Target Recruit Count
- 1201
- Registration Number
- NCT03901482
- Locations
- ๐บ๐ธ
Thomas Jefferson University/Jefferson Headache Center, Philadelphia, Pennsylvania, United States
๐บ๐ธCal Neuro Research Group, Los Angeles, California, United States
๐บ๐ธRapid Medical Research Inc., Cleveland, Ohio, United States
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
Phase 1
Completed
- Conditions
- MigraineMigraine With AuraMigraine Without Aura
- Interventions
- First Posted Date
- 2019-03-14
- Last Posted Date
- 2019-11-26
- Lead Sponsor
- Satsuma Pharmaceuticals, Inc.
- Target Recruit Count
- 46
- Registration Number
- NCT03874832
- Locations
- ๐บ๐ธ
Quotient Sciences Miami Inc., Miami, Florida, United States
ยฉ Copyright 2025. All Rights Reserved by MedPath